MDCO-216

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2016
02420132016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Aim of this study was to demonstrate that MDCO-216 (human recombinant Apolipoprotein A-I Milano) does not induce adverse… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
2017
2017
Reverse lipid transport is critical to maintain homeostasis. Smoking causes lipid accumulation in macrophages, therefore… (More)
Is this relevant?
2016
2016
OBJECTIVE To determine effects of single ascending doses of MDCO-216 on high-density lipoprotein (HDL) subfractions in relation… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
AIMS Apolipoprotein A-1 (ApoA-1), based on epidemiology, is inversely associated with cardiovascular (CV) events. Human carriers… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
2016
2016
BACKGROUND AND AIMS Effects of single ascending doses of MDCO-216 on plasma lipid and lipoprotein levels were assessed in human… (More)
Is this relevant?
2016
2016
Apolipoprotein A-I (apoA-I) is the major protein component of the high-density lipoprotein (HDL) particles. Higher levels of apoA… (More)
Is this relevant?
2014
2014
MDCO-216 is a complex of dimeric ApoA-IMilano and palmitoyl oleoyl phosphatidylcholine (POPC), previously shown to reduce… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
MDCO-216, a complex of dimeric recombinant apoA-IMilano (apoA-IM) and palmitoyl-oleoyl-phosphatidylcholine (POPC), was… (More)
Is this relevant?
2013
2013
HDL delipidation, whole HDL particle infusion with CER-001, MDCO-216, or CSL-112, and gene therapy using HDL-related proteins… (More)
Is this relevant?